Specific Killing of Rb Mutant Cancer Cells by Inactivating TSC2

Cancer Cell

Volumn 17, Issue 5, 2010, Pages 469-480

  Li, Binghui ^a   Gordon, Gabriel M ^a,b   Du, Charles H ^a   Xu, Jinhua ^a   Du, Wei ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

CELLCYCLE

Indexed keywords

LIPID; MANGANESE SUPEROXIDE DISMUTASE; REACTIVE OXYGEN METABOLITE; RETINOBLASTOMA PROTEIN; TUBERIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL DEATH; CELL KILLING; CELL STRESS; CONTROLLED STUDY; DROSOPHILA; ENZYME INDUCTION; GENE INACTIVATION; GENE MUTATION; GENETIC SCREENING; HUMAN; HUMAN CELL; INHIBITION KINETICS; LIPOGENESIS; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION;

EID: 77952101348     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2010.03.019     Document Type: Article

References (44)

1. Balk S.P., and Knudsen K.E. AR, the cell cycle, and prostate cancer. Nucl. Recept. Signal 6 (2008) e001
2. Bosco G., Du W., and Orr-Weaver T.L. DNA replication control through interaction of E2F-RB and the origin recognition complex. Nat. Cell Biol. 3 (2001) 289-295
3. Bracken A.P., Ciro M., Cocito A., and Helin K. E2F target genes: unraveling the biology. Trends Biochem. Sci. 29 (2004) 409-417
4. Crino P.B., Nathanson K.L., and Henske E.P. The tuberous sclerosis complex. N. Engl. J. Med. 355 (2006) 1345-1356
5. De Schrijver E., Brusselmans K., Heyns W., Verhoeven G., and Swinnen J.V. RNA interference-mediated silencing of the fatty acid synthase gene attenuates growth and induces morphological changes and apoptosis of LNCaP prostate cancer cells. Cancer Res. 63 (2003) 3799-3804
6. Demierre M.F., Higgins P.D., Gruber S.B., Hawk E., and Lippman S.M. Statins and cancer prevention. Nat. Rev. Cancer 5 (2005) 930-942
7. Druker B.J. Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML. Oncogene 21 (2002) 8541-8546
8. Du W. Suppression of the rbf null mutants by a de2f1 allele that lacks transactivation domain. Development 127 (2000) 367-379
9. Du W., and Dyson N. The role of RBF in the introduction of G1 regulation during Drosophila embryogenesis. EMBO J. 18 (1999) 916-925
10. Du W., and Pogoriler J. Retinoblastoma family genes. Oncogene 25 (2006) 5190-5200
11. Engelman J.A., and Janne P.A. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin. Cancer Res. 14 (2008) 2895-2899
12. Hallstrom T.C., and Nevins J.R. Specificity in the activation and control of transcription factor E2F-dependent apoptosis. Proc. Natl. Acad. Sci. USA 100 (2003) 10848-10853
13. Hallstrom T.C., Mori S., and Nevins J.R. An E2F1-dependent gene expression program that determines the balance between proliferation and cell death. Cancer Cell 13 (2008) 11-22
14. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
15. Harrington L.S., Findlay G.M., Gray A., Tolkacheva T., Wigfield S., Rebholz H., Barnett J., Leslie N.R., Cheng S., Shepherd P.R., et al. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J. Cell Biol. 166 (2004) 213-223
16. Hatzivassiliou G., Zhao F., Bauer D.E., Andreadis C., Shaw A.N., Dhanak D., Hingorani S.R., Tuveson D.A., and Thompson C.B. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 8 (2005) 311-321
17. Iaquinta P.J., and Lees J.A. Life and death decisions by the E2F transcription factors. Curr. Opin. Cell Biol. 19 (2007) 649-657
18. Igaki T. Correcting developmental errors by apoptosis: lessons from Drosophila JNK signaling. Apoptosis 14 (2009) 1021-1028
19. Inoki K., Li Y., Zhu T., Wu J., and Guan K.L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 4 (2002) 648-657
20. Kubota H. Quality control against misfolded proteins in the cytosol: a network for cell survival. J. Biochem. 146 (2009) 609-616
21. Little J.L., Wheeler F.B., Fels D.R., Koumenis C., and Kridel S.J. Inhibition of fatty acid synthase induces endoplasmic reticulum stress in tumor cells. Cancer Res. 67 (2007) 1262-1269
22. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.G., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350 (2004) 2129-2139
23. Migita T., Ruiz S., Fornari A., Fiorentino M., Priolo C., Zadra G., Inazuka F., Grisanzio C., Palescandolo E., Shin E., et al. Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. J. Natl. Cancer Inst. 101 (2009) 519-532
24. Moon N.S., Frolov M.V., Kwon E.J., Di Stefano L., Dimova D.K., Morris E.J., Taylor-Harding B., White K., and Dyson N.J. Drosophila E2F1 has context-specific pro- and antiapoptotic properties during development. Dev. Cell 9 (2005) 463-475
25. Moon N.S., Di Stefano L., and Dyson N. A gradient of epidermal growth factor receptor signaling determines the sensitivity of rbf1 mutant cells to E2F-dependent apoptosis. Mol. Cell. Biol. 26 (2006) 7601-7615
26. Mulloy R., Ferrand A., Kim Y., Sordella R., Bell D.W., Haber D.A., Anderson K.S., and Settleman J. Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib. Cancer Res. 67 (2007) 2325-2330
27. Nahle Z., Polakoff J., Davuluri R.V., McCurrach M.E., Jacobson M.D., Narita M., Zhang M.Q., Lazebnik Y., Bar-Sagi D., and Lowe S.W. Direct coupling of the cell cycle and cell death machinery by E2F. Nat. Cell Biol. 4 (2002) 859-864
28. Nogueira V., Park Y., Chen C.C., Xu P.Z., Chen M.L., Tonic I., Unterman T., and Hay N. Akt determines replicative senescence and oxidative or oncogenic premature senescence and sensitizes cells to oxidative apoptosis. Cancer Cell 14 (2008) 458-470
29. Ozcan U., Ozcan L., Yilmaz E., Duvel K., Sahin M., Manning B.D., and Hotamisligil G.S. Loss of the tuberous sclerosis complex tumor suppressors triggers the unfolded protein response to regulate insulin signaling and apoptosis. Mol. Cell 29 (2008) 541-551
30. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F.J., Lindeman N., Boggon T.J., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
31. Park Y.B., Park M.J., Kimura K., Shimizu K., Lee S.H., and Yokota J. Alterations in the INK4a/ARF locus and their effects on the growth of human osteosarcoma cell lines. Cancer Genet. Cytogenet. 133 (2002) 105-111
32. Pearce N.J., Yates J.W., Berkhout T.A., Jackson B., Tew D., Boyd H., Camilleri P., Sweeney P., Gribble A.D., Shaw A., and Groot P.H. The role of ATP citrate-lyase in the metabolic regulation of plasma lipids. Hypolipidaemic effects of SB-204990, a lactone prodrug of the potent ATP citrate-lyase inhibitor SB-201076. Biochem. J. 334 (1998) 113-119
33. Potter C.J., Pedraza L.G., and Xu T. Akt regulates growth by directly phosphorylating Tsc2. Nat. Cell Biol. 4 (2002) 658-665
34. Racek T., Buhlmann S., Rust F., Knoll S., Alla V., and Putzer B.M. Transcriptional repression of the prosurvival endoplasmic reticulum chaperone GRP78/BIP by E2F1. J. Biol. Chem. 283 (2008) 34305-34314
35. Robey R.B., and Hay N. Is Akt the "Warburg kinase"?-Akt-energy metabolism interactions and oncogenesis. Semin. Cancer Biol. 19 (2009) 25-31
36. Ron D., and Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat. Rev. Mol. Cell Biol. 8 (2007) 519-529
37. Shah O.J., Wang Z., and Hunter T. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr. Biol. 14 (2004) 1650-1656
38. Steele L., Sukhanova M.J., Xu J., Gordon G.M., Huang Y., Yu L., and Du W. Retinoblastoma family protein promotes normal R8-photoreceptor differentiation in the absence of rhinoceros by inhibiting dE2F1 activity. Dev. Biol. 335 (2009) 228-236
39. Sun Y., Fang Y., Yoon M.S., Zhang C., Roccio M., Zwartkruis F.J., Armstrong M., Brown H.A., and Chen J. Phospholipase D1 is an effector of Rheb in the mTOR pathway. Proc. Natl. Acad. Sci. USA 105 (2008) 8286-8291
40. Tanaka H., Matsumura I., Ezoe S., Satoh Y., Sakamaki T., Albanese C., Machii T., Pestell R.G., and Kanakura Y. E2F1 and c-Myc potentiate apoptosis through inhibition of NF-kappaB activity that facilitates MnSOD-mediated ROS elimination. Mol. Cell 9 (2002) 1017-1029
41. Tanaka-Matakatsu M., Xu J., Cheng L., and Du W. Regulation of apoptosis of rbf mutant cells during Drosophila development. Dev. Biol. 326 (2009) 347-356
42. Wullschleger S., Loewith R., and Hall M.N. TOR signaling in growth and metabolism. Cell 124 (2006) 471-484
43. Yang Q., Inoki K., Kim E., and Guan K.L. TSC1/TSC2 and Rheb have different effects on TORC1 and TORC2 activity. Proc. Natl. Acad. Sci. USA 103 (2006) 6811-6816
44. Zhou X., Ikenoue T., Chen X., Li L., Inoki K., and Guan K.L. Rheb controls misfolded protein metabolism by inhibiting aggresome formation and autophagy. Proc. Natl. Acad. Sci. USA 106 (2009) 8923-8928